dexibuprofen strides 200 mg filmdragerad tablett
strides pharma (cyprus) limited - dexibuprofen - filmdragerad tablett - 200 mg - dexibuprofen 200 mg aktiv substans
dexibuprofen strides 400 mg filmdragerad tablett
strides pharma (cyprus) limited - dexibuprofen - filmdragerad tablett - 400 mg - dexibuprofen 400 mg aktiv substans
dexibuprofen strides 300 mg filmdragerad tablett
strides pharma (cyprus) limited - dexibuprofen - filmdragerad tablett - 300 mg - dexibuprofen 300 mg aktiv substans
tremopen 25 mg/100 mg tablett
fairmed healthcare gmbh - karbidopa (monohydrat); levodopa - tablett - 25 mg/100 mg - levodopa 100 mg aktiv substans; karbidopa (monohydrat) 27 mg aktiv substans
tremopen 12,5 mg/50 mg tablett
fairmed healthcare gmbh - karbidopa (monohydrat); levodopa - tablett - 12,5 mg/50 mg - karbidopa (monohydrat) 13,5 mg aktiv substans; levodopa 50 mg aktiv substans
tremopen 10 mg/100 mg tablett
fairmed healthcare gmbh - karbidopa (monohydrat); levodopa - tablett - 10 mg/100 mg - levodopa 100 mg aktiv substans; karbidopa (monohydrat) 10,8 mg aktiv substans
tremopen 25 mg/250 mg tablett
fairmed healthcare gmbh - karbidopa (monohydrat); levodopa - tablett - 25 mg/250 mg - karbidopa (monohydrat) 27 mg aktiv substans; levodopa 250 mg aktiv substans
colecalciferol strides 20000 ie kapsel, mjuk
strides pharma (cyprus) limited - kolekalciferol - kapsel, mjuk - 20000 ie - kolekalciferol 20000 ie aktiv substans; glycerol hjälpämne
colecalciferol strides 3200 ie kapsel, mjuk
strides pharma (cyprus) limited - kolekalciferol - kapsel, mjuk - 3200 ie - kolekalciferol 3200 ie aktiv substans; glycerol hjälpämne
kauliv
strides pharma (cyprus) limited - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.